1. Search Result
Search Result
Results for "

Psychiatric Disorder

" in MedChemExpress (MCE) Product Catalog:

119

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Peptides

4

Natural
Products

9

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0339
    Primidone
    2 Publications Verification

    TRP Channel RIP kinase Sodium Channel GABA Receptor Necroptosis Neurological Disease Inflammation/Immunology
    Primidone is the orally active inhibitor for TRPM3 (IC50 = 0.6 μM), RIP kinase and voltage-gated sodium channel, and the antagonist for GABA receptor. Primidone can be used as the analgesic and anticonvulsant agent .
    Primidone
  • HY-P6292A

    PACAP Receptor Neurological Disease Inflammation/Immunology Cancer
    KS-133 TFA is a highly selective and potent antagonist of the vascular active enteropeptide receptor 2 (VIPR2) with IC50 values for Ca influx measurement and cAMP measurement of 24.8 nM and 500 nM, respectively. KS-133 TFA reverses the tumor-promoting M2 phenotype of tumor-associated macrophages to the anti-tumor M1 phenotype, alters the tumor immune microenvironment, and inhibits tumor growth. KS-133 TFA can be used for research on schizophrenia and cancer immune regulation .
    KS-133 TFA
  • HY-13204A

    KL 373

    mAChR Neurological Disease
    Biperiden (KL 373) is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden has the potential for the research of Parkinson's disease and other related psychiatric disorders .
    Biperiden
  • HY-156601

    LP352

    5-HT Receptor Neurological Disease
    Bexicaserin (LP352) is a 5-HT2C receptor agonist with potential for studying obesity and psychiatric-related disorders (such as epilepsy) .
    Bexicaserin
  • HY-12152
    PNU-120596
    1 Publications Verification

    NSC 216666

    nAChR Neurological Disease Inflammation/Immunology
    PNU-120596 (NSC 216666) is a potent and selective α7 nAChR positive allosteric modulator (PMA) that can cross the blood-brain barrier, with an EC50 of 216 nM. PNU-120596 is inactive against α4β2, α3β4, and α9α10 nAChRs. PNU-120596 has the potential for psychiatric and neurological disorders research .
    PNU-120596
  • HY-16716
    Basmisanil
    1 Publications Verification

    RG1662; RO5186582

    GABA Receptor Neurological Disease
    Basmisanil (RG1662) is a highly selective orally active α subunit-containing GABAA receptors (GABAAα5) negative allosteric modulator (NAMs). Basmisanil can inhibit GABAA-α5 with a Ki value of 5 nM and IC50 value of 8 nM, respectively. Basmisanil can be used for the research of multiple cognitive and psychiatric disorders .
    Basmisanil
  • HY-B1487

    Tricyclamol hydrochloride; (±)-Procyclidine hydrochloride

    iGluR mAChR Neurological Disease
    Procyclidine (Tricyclamol, (±)-Procyclidine) hydrochloride , an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine hydrochloride can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy .
    Procyclidine hydrochloride
  • HY-13204

    KL 373 hydrochloride

    mAChR Neurological Disease
    Biperiden (KL 373) hydrochloride is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden hydrochloride has the potential for the research of Parkinson's disease and other related psychiatric disorders .
    Biperiden hydrochloride
  • HY-19733

    ITI-007 tosylate

    5-HT Receptor Dopamine Receptor Neurological Disease Cancer
    Lumateperone (ITI-007) tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone tosylate has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia .
    Lumateperone tosylate
  • HY-116451
    PF-04859989 hydrochloride
    1 Publications Verification

    Aminotransferases (Transaminases) Neurological Disease
    PF-04859989 hydrochloride is a brain-penetrant, irreversible kynurenine aminotransferase (KAT) II inhibitor with IC50s of 23 and 263 nM for hKAT II and rKAT II. PF-04859989 hydrochloride is selective for KAT II over human KAT I, KAT III, and KAT IV (IC50s of 22, 11, and >50 μM, respectively) .
    PF-04859989 hydrochloride
  • HY-15522
    WAY-267464
    2 Publications Verification

    Oxytocin Receptor Neurological Disease
    WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .
    WAY-267464
  • HY-110175
    CX614
    1 Publications Verification

    iGluR Neurological Disease
    CX614 is a positive variant modulator of AMPA receptors that enhances excitatory postsynaptic potentials (amplitude and duration) by blocking and slowing the inactivation of responses to glutamate and automatically evokes excitatory postsynaptic currents in neuronal cultures. CX614 can be used in the study of psychiatric disorders such as depression .
    CX614
  • HY-W250174

    3,5-Diiodosalicylic acid lithium salt

    Biochemical Assay Reagents Others
    Lithium 3,5-diiodosalicylate is a compound used in the study of bipolar disorder and other psychiatric disorders. It contains lithium and a salicylate. Lithium 3,5-diiodosalicylate works by affecting the levels of certain neurotransmitters in the brain, including dopamine and serotonin.
    Lithium 3,5-diiodosalicylate
  • HY-109164

    AGN-241751; GATE-251

    iGluR Neurological Disease
    Zelquistinel (AGN-241751) is the orally active N-methyl-D-aspartate (NMDA) receptor partial agonist used for the research of depression, anxiety and other related psychiatric disorders .
    Zelquistinel
  • HY-B1693
    Levomepromazine
    1 Publications Verification

    Methotrimeprazine

    5-HT Receptor Dopamine Receptor Histamine Receptor Autophagy Enterovirus Calcium Channel Infection Neurological Disease Inflammation/Immunology
    Levomepromazine (Methotrimeprazine) is an orally active antipsychotic compound and Ca 2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca 2+ levels. Levomepromazine has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine can induce adaptive ER stress and autophagy. In addition, Levomepromazine has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine can be used in the study psychiatric disorders and relieving nausea and vomiting .
    Levomepromazine
  • HY-124607B
    BRD3731
    2 Publications Verification

    GSK-3 Neurological Disease Metabolic Disease
    BRD3731 is a selective GSK3β inhibitor, with IC50s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 is potentail for the research of post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorders .
    BRD3731
  • HY-13999

    NSI-189

    Trk Receptor Neurological Disease
    Amdiglurax (NSI-189) is an orally active chemical entity with enhanced neurogenic activity. Amdiglurax up-regulates neurogenic factors such as BDNF (brain derived-neurotrophic factor) and SCF. Amdiglurax exhibits anti-depressant effect. Amdiglurax enhances synaptic plasticity and reduces cognitive dysfunction. Amdiglurax holds potential for psychiatric disorder research .
    Amdiglurax
  • HY-137790
    Bicuculline methochloride
    35+ Cited Publications

    (-)-Bicuculline methochloride

    GABA Receptor Neurological Disease
    Bicuculline ((+)-Bicuculline; d-Bicuculline) methochloride is a selective GABAA receptor antagonist with an IC50 value of 3 μM. Bicuculline methochloride induces clonic tonic convulsions in mammals and can also be used to block Ca 2+ activated potassium channels. Bicuculline methochloride can be used in studies of epilepsy and other related psychiatric disorders .
    Bicuculline methochloride
  • HY-159829

    NBI-1117568; HTL-0016878

    mAChR Neurological Disease
    Direclidine (NBI-1117568, HTL-0016878) is a selective orthosteric agonist targeting the muscarinic acetylcholine M4 receptor, exhibiting very low affinity for M1, M2, M3, and M5 receptors. It binds to the orthosteric site of the M4 receptor in a non-covalent, competitive manner. Direclidine specifically activates the M4 receptor, inhibiting the release of acetylcholine from striatal cholinergic interneurons, thereby regulating the balance of the dopaminergic system and reducing psychiatric symptoms associated with excessive dopamine release. Direclidine can improve symptoms associated with neuropsychiatric disorders and is used in research on schizophrenia and other neuropsychiatric disorders .
    Direclidine
  • HY-B1482A

    TPS-23

    Potassium Channel Neurological Disease
    Mesoridazine (TPS-23) , a metabolite of Thioridazine (HY-B0965A), acts as an orally active phenothiazine antipsychotic agent. Mesoridazine is a potent and rapid open-channel blocker of human ether-a-go-go related gene (hERG) channels and blocks hERG currents with an IC50 of 550 nM (at 0 mV) in human embryonic kidney 293 cells .Mesoridazine can be used for the research of schizophrenia, as well as certain other psychiatric disorders .
    Mesoridazine
  • HY-130125

    EAAT Neurological Disease
    SLC1A1/EAAT3-IN-1 (Compound 3e) is a selective EAAT3 inhibitor with an IC50 of 7.2  μM for hEAAT3 over EAAT1,2,4 (IC50: ∼ 250 μM). SLC1A1/EAAT3-IN-1 can be used for psychiatric disorders such as obsessive compulsive disorder and schizophrenia research .
    SLC1A1/EAAT3-IN-1
  • HY-153530

    IPK Superfamily Neurological Disease Metabolic Disease
    LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC50 values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders .
    LI-2242
  • HY-108679
    WAY-267464 hydrochloride
    2 Publications Verification

    Oxytocin Receptor Neurological Disease
    WAY-267464 (hydrochloride) is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 (hydrochloride) can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 (hydrochloride) can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .
    WAY-267464 hydrochloride
  • HY-122805

    Ser/Thr Protease Neurological Disease
    PF-794 is a potent, selective and ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with an IC50 of 39 nM. PF-794 shows selective for the TNIK family. PF-794 reduces endogenous p120-catenin phosphorylation in cells. PF-794 can be used for teh study of psychiatric disorders .
    PF-794
  • HY-175442

    iGluR Neurological Disease
    GluN1/3A-IN-2 (Compound DD-1) is a selective GluN1/GluN3A NMDA receptor inhibitor with an IC50 of 1.26  μM for GluN1/GluN3A NMDA receptor. GluN1/3A-IN-2 can be used for neurological and psychiatric disorders research .
    GluN1/3A-IN-2
  • HY-103429

    LY163502

    Dopamine Receptor Neurological Disease
    Quinelorane dihydrochloride (LY163502) is a potent dopamine D3/D2 receptor agonist. Quinelorane has the potential for neurological and psychiatric disorders research .
    Quinelorane dihydrochloride
  • HY-13456

    iGluR Neurological Disease
    LY-404187 is a potent, selective and centrally active positive allosteric modulator of AMPA receptors, with the EC50s of 5.65, 0.15, 1.44, 1.66 and 0.21 µM for GluR1i, GluR2i, GluR2o, GluR3i and GluR4i, respectively. LY-404187 has therapeutic potential in a number of psychiatric disorders and neurodegenerative diseases .
    LY-404187
  • HY-148325

    nAChR Neurological Disease
    α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder) .
    α7 Nicotinic receptor agonist-1
  • HY-175511

    5-HT Receptor Neurological Disease
    5-HT2A agonist 7 (Compound 45) is an orally active and highly selective serotonin receptor 2A (5-HT2A) agonist (EC50=12 nM). 5-HT2A agonist 7 is promising for research of psychiatric disorders such as depression .
    5-HT2A agonist 7
  • HY-18078

    Phosphodiesterase (PDE) Neurological Disease
    PQ-10 is a potent inhibitor of Phosphodiesterase 10A (PDE10A) with IC50 andED50 of 4.6 nM and 13 mg/kg, respectively. PQ-10 induces patterns of brain glucose metabolism which can be a potential translational biomarker. PQ-10 has the potential for researching psychiatric disorders like schizophrenia .
    PQ-10
  • HY-13999A1

    NSI-189 phosphate

    Trk Receptor Neurological Disease
    Amdiglurax (NSI-189) phosphate is an orally active chemical entity with enhanced neurogenic activity. Amdiglurax phosphate up-regulates neurogenic factors such as BDNF (brain derived-neurotrophic factor) and SCF. Amdiglurax phosphate exhibits anti-depressant effect. Amdiglurax enhances synaptic plasticity and reduces cognitive dysfunction. Amdiglurax phosphate holds potential for psychiatric disorder research .
    Amdiglurax phosphate
  • HY-101490

    Phosphodiesterase (PDE) Neurological Disease
    PDE1-IN-2 is a PDE1 inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC50 values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectvely. PDE1-IN-2 is developed for the research of neurodegenerative disorders and psychiatric disorders .
    PDE1-IN-2
  • HY-134661

    GPR6 Neurological Disease
    (S)-CVN424 is a potent G-Protein-Coupled Receptor 6 (GPR6) modulator. (S)-CVN424 has the potential for a variety of neurological and psychiatric disorders research, including Parkinson's disease .
    (S)-CVN424
  • HY-117292
    DAO-IN-2
    1 Publications Verification

    Amino Acid Oxidase Neurological Disease
    DAO-IN-2 is a d-amino acid oxidase (DAO) inhibitor (h-DAO IC50 = 245 nM). DAO-IN-2 is a moderate inhibitor of DAAO in vitro and in vivo. DAO-IN-2 can be used to study DAAO-related psychiatric disorders .
    DAO-IN-2
  • HY-100783B

    (+)-Bicuculline methobromide

    GABA Receptor Neurological Disease
    Bicuculline methobromide is a selective GABAA Receptor antagonist with an IC50 value of 3 μM. Bicuculline methobromide induces clonic tonic convulsions in mammals and can also be used to block Ca 2+ activated potassium channels. Bicuculline methobromide can be used in studies of epilepsy and other related psychiatric disorders .
    Bicuculline methobromide
  • HY-141495A

    (-)-PW0464

    Drug Isomer Dopamine Receptor Neurological Disease
    Razpipadon ((-)-PW0464) is an isomer of (Rac)-Razpipadon (HY-141495).
    Razpipadon
  • HY-A0243

    1664CB; Acepromethazine

    Histamine Receptor Neurological Disease
    Aceprometazine (1664CB) is an orally active antipsychotic. Aceprometazine can be used in the study of psychiatric disorders, such as depression .
    Aceprometazine
  • HY-116076

    5-HT Receptor Neurological Disease
    S-15535 is a highly selective 5-HT1A receptor ligand. S-15535 is an antagonist of postsynaptic 5-HT1A receptors and an agonist of presynaptic 5-HT1A receptors. S-15535 can be used in research on psychiatric disorders, such as anti-anxiety .
    S-15535
  • HY-161511

    5-HT Receptor Neurological Disease
    LPH-5 is a selective 5-HT2A receptor agonist (EC50=190 nM). LPH-5 works by selectively activating the 5-HT2A receptor, which may be involved in regulating mood, perception, and other central nervous system functions associated with the 5-HT2A receptor. LPH-5 can be used to further explore the 5-HT2A receptor in psychiatric disorders, including depression, anxiety, and substance abuse disorders .
    LPH-5
  • HY-107664A

    Neurotensin Receptor Neurological Disease
    SR 142948 dihydrochloride is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC50s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. SR 142948 dihydrochloride antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC50 of 3.9 nM. SR 142948 dihydrochloride blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 dihydrochloride shows blood-brain permeability and can be used in study of psychiatric disorders .
    SR 142948 dihydrochloride
  • HY-101841

    mAChR Neurological Disease
    LY 2033298 is a selective positive allosteric modulator of the muscarinic M4 receptor. LY 2033298 can be used in the study of psychiatric disorders .
    LY 2033298
  • HY-156817

    TNF Receptor Neurological Disease
    TNIK-IN-6 (Compound 9) is an inhibitor of Traf2 and Nck-interacting kinase (TNIK) and , with IC50 of 0.93 μM, that plays important roles in neurological and psychiatric disorders .
    TNIK-IN-6
  • HY-W773779

    GSK-3 Neurological Disease Metabolic Disease Cancer
    GSK3-IN-9 (Compound 0713) is a selective glycogen synthase kinase 3 (GSK3) inhibitor. GSK3-IN-9 Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder .
    GSK3-IN-9
  • HY-B1487R

    Tricyclamol hydrochloride (Standard); (±)-Procyclidine hydrochloride (Standard)

    Reference Standards iGluR mAChR Neurological Disease
    Procyclidine (hydrochloride) (Standard) is the analytical standard of Procyclidine (hydrochloride). This product is intended for research and analytical applications. Procyclidine (Tricyclamol, (±)-Procyclidine) hydrochloride , an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine hydrochloride can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy .
    Procyclidine hydrochloride (Standard)
  • HY-W648166

    Dopamine Receptor Neurological Disease
    Dopamine D2 receptor antagonist-3 (Example 17) is an orally active and selective dopamine D2 receptor antagonist with a pIC50 of 5.52. Dopamine D2 receptor antagonist-3 exhibits antipsychotic activity in the Apomorphine (HY-12723) induced agitation in rats. Dopamine D2 receptor antagonist-3 can be used for psychiatric and neurological disorders research .
    Dopamine D2 receptor antagonist-3
  • HY-179108

    iGluR Neurological Disease
    NMDAR modulator 1 (Compound 12) is a positive, allosteric GluN1/GluN2B receptor modulator. NMDAR modulator 1 enhances NMDAR current. NMDAR modulator 1 can be used in the research of psychiatric disorders .
    NMDAR modulator 1
  • HY-119114

    CRFR Neurological Disease
    E-2508 free base is an orally active and highly selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist with anxiolytic effects (Ki=11 nM). E-2508 free base blocks CRF-induced cAMP accumulation via CRF1 receptor inhibition. E-2508 free base is promising for research of stress-related psychiatric disorders, such as anxiety and depression .
    E-2508 free base
  • HY-118635

    Actebral

    Radionuclide-Drug Conjugates (RDCs) Neurological Disease
    Cyprodenate is an orally active and blood-brain barrier-penetrant stimulant. Cyprodenate can be labeled with 14C. Cyprodenate can be used in the research of psychiatric disorders .
    Cyprodenate
  • HY-137161

    DU24565

    Serotonin Transporter Neurological Disease
    6-Nitroquipazine (DU24565) is a potent and selective 5-HT transporter inhibitor, with a Ki of 0.17 nM. 6-Nitroquipazine can be used in the research of psychiatric disorders such as depression .
    6-Nitroquipazine
  • HY-168537

    Dopamine Receptor 5-HT Receptor Neurological Disease
    LB-102 is an orally active inhibitor of dopamine D2, D3, and 5-HT7 receptors, which can be used in research on schizophrenia and other psychiatric disorders .
    LB-102

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: